

# A Phase 1 Study of WVE-007 in Adults Living With Overweight or Obesity

NCT06842186

---

Status	RECRUITING
Phase	Phase 1
Sponsor	Wave Life Sciences Ltd.
Enrollment	136 participants

## Key Eligibility Criteria

---

### Inclusion (3)

- Male and female participants aged 18 to 60 years
- BMI 28 to 35 kg/m<sup>2</sup> which has been stable ( $\pm 5\%$ ) for the previous 3 to 6 months (based on participant self-report or medical records)
- Healthy, in the opinion of the Investigator, as determined by prestudy medical history, physical examination, and clinical laboratory assessments

### Exclusion (5)

- History or presence of CV disease, including heart failure (New York Heart Association \[NYHA\] Class III or IV), myocardial infarction, angina, or clinically significant abnormal laboratory assessments
- History or presence of thyroid disorders
- Medical history or diagnosis of causes of liver disease
- Use of any siRNA agent in the prior 12 months
- Received an investigational agent within 90 days or 5 half-lives, whichever is longer, before the first dose of study drug or are in follow-up of another clinical study

## Locations (6 total)

---

Parexel International-EPCU Baltimore, Baltimore, Maryland, United States  
ARENSIA Research Clinic, Chisinau, Moldova  
Arensia Clinics S.R.L., Bucharest, Romania  
... and 3 more locations

---

<https://clinicaltrials.gov/study/NCT06842186>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.